The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Phase II GRIFFIN study topline results released
The phase II GRIFFIN study (MMY2004, NCT02874742) investigated the use of daratumumab (dara) in combination with bortezomib (V), lenalidomide (R), and dexamethasone (d; dara-VRd) in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for high-dose chemotherapy and autologous stem cell transplant (ASCT). This was compared to VRd alone1
During the American Society of Hematology (ASH) meeting in San Diego, US, 2018, study investigators reported the quadruplet regimen (dara-VRd) had a manageable toxicity profile, and achieved minimal residual disease (MRD) negativity (10-5) in 50% of patients post-consolidation.2
It has now been announced that the study has met its primary endpoint with a higher percentage of patients achieving a stringent complete response (sCR) with dara-VRd compared to VRd alone.1
Given as dara-VRd versus VRd unless otherwise stated
-
Study design:
This randomized, open-label study compared dara-VRd to VRd in 223 patients. The primary endpoint was sCR post-consolidation1 -
Efficacy:1
- sCR: 42.4% vs 32.0%
- Odds ratio: 1.57
- 95% CI, 0.87-2.82
- p = 0.1359
- Odds ratio: 1.57
- This exceeded the statistical significance at the pre-set 2-sided alpha level of 0.2
- sCR: 42.4% vs 32.0%
-
Safety:
- The safety profile of the dara-VRd quadruplet was similar to that reported for the drugs when used separately.1
-
Future directions:
- The company responsible for the study has initiated two phase III studies – PERSEUS and CEPHEUS in frontline multiple myeloma (MM) indications.1
Conclusion
These results add to the evidence that the addition of daratumumab to traditional triplet induction regimens can improve efficacy. This was supported by the CASSIOPEIA, part one, trial results which showed that daratumumab in combination with V + thalidomide (T) + d (dara-VTd), improved efficacy in the transplant eligible, NDMM setting. In the CASSIOPEIA trial, dara-VTd gave a 53% reduction in the risk of progression or death compared to VTd alone.3
The development of an optimal induction regimen for ASCT has evolved significantly in recent years, and was discussed by Professor Mohamad Mohty during the 45th Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 2019. During this presentation, Professor Mohty noted that the GRIFFIN trial, using daratumumab in combination with a traditional triplet, like VRd, creating a quadruplet (dara-VRd), was one of the most recent innovations in ASCT induction regimen optimization.4
Additionally, the recent results of the COLUMBA trial, showing subcutaneous administration of daratumumab is non-inferior to intravenous administration, may further increase uptake of daratumumab-containing regimens, whilst increasing the patient’s quality of life during treatment.5
References